Research Topics
| Luca GianniSummaryAffiliation: Istituto Nazionale Tumori Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes failsCristiana Sessa
Southern Europe New Drugs Organization Foundation, Via Visconti di Modrone 12, 20100 Milano, Italy
J Clin Oncol 23:1867-74. 2005..To assess the efficacy and toxicity of the marine-derived alkaloid trabectedin (ET-743) in patients with advanced ovarian cancer refractory to or experiencing disease relapse after platinum- and taxane-based chemotherapy...- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HERLuca Gianni
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Lancet 375:377-84. 2010..We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab... - Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanesLuca Gianni
Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, ViaVenezian 1, Milan 20133, Italy
Cardiovasc Toxicol 7:67-71. 2007.... - Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatLuca Gianni
Oncologia Medica 1, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
J Clin Oncol 28:1131-7. 2010..The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored... - Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerLuca Gianni
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
J Clin Oncol 27:2474-81. 2009..To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy... - Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapyLuca Gianni
Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
Clin Cancer Res 11:8715-21. 2005..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate... - Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancerGabriella Mariani
Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
Nat Clin Pract Oncol 6:93-104. 2009..Current data do not support the use of trastuzumab for more than 1 year. The analysis of 2-year treatment with trastuzumab is expected to be available in 2009... - 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyGianni Bonadonna
Istituto Nazionale Tumori, 20133 Milan, Italy
BMJ 330:217. 2005.... - Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy studyGabriella Mariani
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Clin Breast Cancer 7:321-5. 2006.... - Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancerGianni Bonadonna
Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
J Clin Oncol 22:1614-20. 2004..To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse... - Cardiotoxic effects of anthracycline-taxane combinationsAntonella Perotti
Division of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumouri, 20133 Milan, Italy
Expert Opin Drug Saf 2:59-71. 2003..Furthermore, there are experimental data indicating that DTX can also stimulate the metabolism of DOX to toxic species in human heart... - Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancerGiulia Bianchi
Istituto Nazionale Tumori, Milan, Italy
Clin Cancer Res 9:5944-51. 2003..Congestive heart failure was not observed, and LVEF decreases were reversible. Further studies of this regimen are warranted... - Role of anthracyclines in the treatment of early breast cancerLuca Gianni
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
J Clin Oncol 27:4798-808. 2009..To review data relating to anthracyclines in the adjuvant treatment of early breast cancer... - AnthracyclinesLuca Gianni
Division of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
Cancer Chemother Biol Response Modif 21:29-40. 2003 - Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression levelManuela Campiglio
Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
J Cell Physiol 198:259-68. 2004..Our data suggest that the antitumor activity of ZD1839 is due to a cytostatic effect, and involves apoptosis induction in a subset of sensitive cells only, and that neither MAPK nor Akt is a reliable marker of ZD1839 activity... - Anthracycline cardiotoxicity: from bench to bedsideLuca Gianni
Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy
J Clin Oncol 26:3777-84. 2008..Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues... - Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancerGiulia Bianchi
Fondazione IRCCS Istituto Tumori di Milano, Via Venezian, 1, 20133 Milan, Italy
Anticancer Drugs 20:616-24. 2009..Further investigation of single-agent sorafenib in this patient population is not recommended; however, studies investigating combinations of sorafenib with chemotherapeutic agents are warranted and ongoing... - Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerLuca Gianni
Medical Oncology, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
J Clin Oncol 23:7265-77. 2005..We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk... - Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni
Department of Medical Oncology, San Raffaele Institute, Milan, Italy
Lancet Oncol 12:236-44. 2011..We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial... - The future of targeted therapy: combining novel agentsLuca Gianni
Division of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, I 20133 Milan, Italy
Oncology 63:47-56. 2002..It is possible that through the development and use of biological anticancer agents, such as Herceptin, future anticancer regimens may be specifically tailored to each patient based on their molecular characteristics... - Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumoursNicola Nicolai
Urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
BJU Int 104:340-6. 2009.... - Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancerGiampaolo Bianchini
Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Cancer Res 70:8852-62. 2010..Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype... - The choice of the correct imaging modality in breast cancer managementEmilio Bombardieri
Division of Nuclear Medicine, PET Centre, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Eur J Nucl Med Mol Imaging 31:S179-86. 2004..There is a need for further prospective evaluations with appropriate clinical trials designed to evaluate the impact of these approaches in improving survival and quality of life... - Breast cancer: diagnostic and therapeutic optionsEmilio Bombardieri
Division of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Eur J Nucl Med Mol Imaging 31:S1-2. 2004 - AnthracyclinesLuca Gianni
Istituto Nazionale Tumori, Milan, Italy
Cancer Chemother Biol Response Modif 20:59-69. 2002 - Targeting the epidermal growth factor receptor a new strategy in cancer treatmentLuca Gianni
Progetto Montabone per lo Sviluppo di Nuove Terapie, Istituto Nazionale dei Tumori, Milan, Italy
Suppl Tumori 1:S60-1. 2002 - Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLuca Gianni
Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
Lancet Oncol 13:25-32. 2012..We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting... - Targeting TRAIL agonistic receptors for cancer therapyCarmelo Carlo Stella
Cristina Gandini Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
Clin Cancer Res 13:2313-7. 2007..The clinical translation of cell and gene therapy approaches represent a challenging strategy that might achieve systemic tumor targeting and increased intratumor delivery of the therapeutic agent... - Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosingCristiana Sessa
Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500 Bellinzona, Switzerland
Eur J Cancer 42:171-8. 2006..These findings are in agreement with the presence of saturable absorption and metabolic induction. The peculiar pharmacokinetics and >99% protein binding discouraged further clinical development of oral SU006668 in humans... - International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendationsManfred Kaufmann
Department of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
J Clin Oncol 21:2600-8. 2003..Recommendations are made regarding terminology, indications, regimen, diagnosis before treatment, monitoring of efficacy, tumor localization, surgery, pathologic evaluation, and postoperative treatment... - Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityGiorgio Minotti
G d Annunzio University School of Medicine, Centro Studi Sull Invecchiamento, Room 412, Via dei Vestini, 66013 Chieti, Italy
Pharmacol Rev 56:185-229. 2004..An overview of these issues confirms that anthracyclines remain "evergreen" drugs with broad clinical indications but have still an improvable therapeutic index... - Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapiesEmanuela Salvatorelli
Department of Drug Sciences and Center of Excellence on Aging, G d Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy
J Pharmacol Exp Ther 320:790-800. 2007..The failure of paclitaxel or docetaxel to stimulate epirubicinol formation therefore uncovers an important determinant of the improved cardiac tolerability of epirubicin-taxane combinations... - The "other" signaling of trastuzumab: antibodies are immunocompetent drugsLuca Gianni
J Clin Oncol 26:1778-80. 2008 - The cost of life: should it matter to doctors?Luca Gianni
Ann Oncol 17:357-8. 2006 - Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapiesEmanuela Salvatorelli
Department of Drug Sciences and Center of Excellence on Aging, G. d'Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy
J Pharmacol Exp Ther 318:424-33. 2006..This information serves metabolic insights into the risk of cardiotoxicity induced by doxorubicin-taxane therapies... - Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancerLajos Pusztai
Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
Nat Clin Pract Oncol 1:44-50. 2004..Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction... - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart
Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
N Engl J Med 353:1659-72. 2005..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy... - Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable diseaseJulie R Gralow
Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
J Clin Oncol 26:814-9. 2008..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer... - Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron additionEmanuela Salvatorelli
Center of Excellence on Aging, G. d'Annunzio University School of Medicine, 66013 Chieti, Italy
J Biol Chem 281:10990-1001. 2006..These results uncover the molecular determinants of the reduced cardiotoxicity of epirubicin and serve mechanism-based guidelines to improving antitumor therapies... - Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitineGiulia Bianchi
Medical Oncology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
Eur J Cancer 41:1746-50. 2005..In view of its effect in improving established paclitaxel- and cisplatin-neuropathy, we recommend ALC testing in preventing progression or revert symptoms during neurotoxic chemotherapy... - Ixabepilone and the narrow path to developing new cytotoxic drugsLuca Gianni
J Clin Oncol 25:3389-91. 2007 - Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
Clin Cancer Res 9:2040-8. 2003..They appeared to be a sensitive tool to monitor clinical changes for the five tumor types in these trials and showed that ZD1839 has the potential to improve patients' QoL...